Adams Diversified Equity Fund Inc. Has $34.66 Million Stake in Eli Lilly and Company (NYSE:LLY)

Adams Diversified Equity Fund Inc. lowered its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 15.7% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 41,968 shares of the company's stock after selling 7,800 shares during the period. Eli Lilly and Company makes up 1.4% of Adams Diversified Equity Fund Inc.'s portfolio, making the stock its 15th largest holding. Adams Diversified Equity Fund Inc.'s holdings in Eli Lilly and Company were worth $34,662,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of LLY. GAMMA Investing LLC boosted its holdings in Eli Lilly and Company by 103,831.6% in the 1st quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock valued at $12,278,292,000 after purchasing an additional 14,852,076 shares during the period. Norges Bank acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $8,407,908,000. Proficio Capital Partners LLC boosted its stake in shares of Eli Lilly and Company by 100,387.1% in the fourth quarter. Proficio Capital Partners LLC now owns 5,202,215 shares of the company's stock valued at $4,016,110,000 after buying an additional 5,197,038 shares during the period. Wellington Management Group LLP grew its position in Eli Lilly and Company by 19.0% during the fourth quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company's stock worth $9,747,214,000 after buying an additional 2,012,129 shares in the last quarter. Finally, Capital International Investors grew its position in Eli Lilly and Company by 23.2% during the fourth quarter. Capital International Investors now owns 8,730,758 shares of the company's stock worth $6,740,272,000 after buying an additional 1,645,222 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Trading Down 2.4%

Shares of LLY stock traded down $18.94 during trading hours on Friday, hitting $776.18. 4,109,419 shares of the company's stock traded hands, compared to its average volume of 3,682,356. The stock has a market cap of $735.61 billion, a PE ratio of 63.16, a price-to-earnings-growth ratio of 1.16 and a beta of 0.40. The stock's 50 day simple moving average is $781.50 and its 200 day simple moving average is $800.11. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). The company had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The firm's revenue for the quarter was up 45.2% on a year-over-year basis. During the same period in the prior year, the business earned $2.58 earnings per share. On average, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be given a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.77%. Eli Lilly and Company's dividend payout ratio (DPR) is 48.82%.

Wall Street Analyst Weigh In

LLY has been the subject of a number of analyst reports. UBS Group dropped their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Cantor Fitzgerald assumed coverage on shares of Eli Lilly and Company in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 target price for the company. The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and reduced their price target for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. Guggenheim reissued a "buy" rating and issued a $936.00 price objective on shares of Eli Lilly and Company in a research note on Friday, June 20th. Finally, HSBC cut Eli Lilly and Company from a "buy" rating to a "reduce" rating and cut their target price for the stock from $1,150.00 to $700.00 in a research note on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $1,011.61.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.